The Role of Precision Dosing and Therapeutic Drug Monitoring in Precision Oncology: A Single-centre Experience with Everolimus

Purpose Targeted cancer therapies often use a ‘one-size-fits-all’ dosing strategy, despite significant variability in individual drug exposure and its effect on both efficacy and toxicity. Therapeutic drug monitoring (TDM) is a precision dosing method that measures drug levels to guide dosing. This single-centre review investigates the potential benefits of TDM in cancer patients prescribed everolimus. Methods Medical records from Flinders Medical Centre, a public tertiary hospital in South Australia, were retrospectively reviewed for patients treated with everolimus for cancer indications between January 1, 2013, and December 31, 2023. Data on whole blood everolimus concentrations, cancer diagnoses, dosing regimens, survival outcomes and demographics were collected and analysed. Results During the study period, 53 patients with a median age of 64 years (range: 38-85) were treated with everolimus for oncological indications. Diagnoses included metastatic breast cancer (MBC, n = 41), metastatic renal cancer (n = 6), neuroendocrine tumours (n = 4) and recurrent ovarian cancer (n = 2). Among these, 14 patients (26%) underwent at least one everolimus blood level assessment. All MBC patients who underwent TDM-guided dose adjustments avoided treatment discontinuation due to adverse effects. Conclusion Prospective studies are warranted to establish therapeutic ranges and confirm the clinical benefits of TDM in cancer care.

• Publication year

  2025

• Venue

  Journal of Current Oncology

• Publication date

  2025-06-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1177/25898892251405650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

  2024influential reference
• Optimizing Tomorrow's Drug Development with Project Optimus: Precision Dosing IS Precision Oncology.

  2024cited by this paper
• Recent Advances Addressing the Challenges of Precision Dosing

  2024cited by this paper
• Dose Optimization of Targeted Therapies for Oncologic Indications

  2024cited by this paper
• Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists

  2024cited by this paper
• First reported double drug–drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature

  2023cited by this paper
• A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

  2022cited by this paper
• Precision Dosing of Targeted Therapies Is Ready for Prime Time

  2021cited by this paper
• An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients.

  2021cited by this paper
• Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients

  2020cited by this paper
• Anticancer drugs are not well tolerated in all older patients with cancer.

  2020cited by this paper
• Therapeutic drug monitoring of Everolimus in oncology: evidences and perspectives.

  2019influential reference
• User's guide to correlation coefficients

  2018cited by this paper
• Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure‐effect relationship

  2017cited by this paper
• The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma

  2017cited by this paper
• Therapeutic Drug Monitoring of Everolimus: A Consensus Report

  2016cited by this paper
• Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers

  2015cited by this paper
• Cellular and molecular effects of the mTOR inhibitor everolimus.

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.

  2014cited by this paper
• Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

  2014influential reference
• Therapeutic drug monitoring in cancer--are we missing a trick?

  2014cited by this paper
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  2012cited by this paper
• Phase 3 trial of everolimus for metastatic renal cell carcinoma

  2010cited by this paper
• Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

  2010cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009influential reference
• Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

  2009influential reference

• No citing papers are available for this paper.